Blood cell therapy最新文献

{"title":"The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.","authors":"Takashi Shimakawa, Noriaki Kawano, Yuichiro Semba, Yasuo Mori, Ken Takigawa, Takuji Yamauchi, Kohta Miyawaki, Fumiaki Jinnouchi, Teppei Sakoda, Kyohei Mori, Masatoshi Shimo, Masahiro Otsu, Riichiro Ikeda, Shunya Shiraishi, Takashi Nakaike, Kiyoshi Yamashita, Koichi Mashiba, Ikuo Kikuchi, Kousuke Marutsuka, Koichi Ohshima, Sawako Matsuzaki, Kennosuke Karube, Koji Kato, Takahiro Maeda, Koichi Akashi","doi":"10.31547/bct-2024-037","DOIUrl":"10.31547/bct-2024-037","url":null,"abstract":"<p><strong>Background: </strong>Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for relapsed or refractory non-Hodgkin lymphoma, achieving a 5-year overall survival rate of 40-50%. However, relapse remains a major challenge, especially due to CD19-negative clones. Epcoritamab, a bispecific antibody targeting CD20 and CD3, offers a potential solution for post-CAR-T relapse; however, clinical data in this setting remain limited, particularly in Japan.</p><p><strong>The case: </strong>A 68-year-old woman with CD5-positive diffuse large B-cell lymphoma (DLBCL) relapsed multiple times following various treatments, including CAR-T therapy. Genetic profiling revealed a <i>MYD88/CD79B</i>-mutated (MCD) subtype with CD19-negative clones resistant to CAR-T cells. Given her high tumor burden, she received debulking therapy followed by epcoritamab treatment. Despite concerns about tumor lysis syndrome, cytokine release syndrome, and neurotoxicity, no significant adverse events occurred. The patient achieved a complete remission, demonstrating the efficacy and safety of this approach.</p><p><strong>Conclusion: </strong>This case highlights the potential of epcoritamab combined with debulking therapy for treating CAR-T-refractory CD19-negative DLBCL. This is the first validated case in Japan showing that epcoritamab is a viable and safe treatment option for post-CAR-T relapse, addressing a critical unmet need in the current therapeutic landscape.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"8 3","pages":"244-249"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12414653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Composite Measurable Residual Disease Assessment with PET-CT and flow cytometry in Multiple Myeloma patients undergoing Autologous Transplant.","authors":"Rudra Narayan Swain, Arihant Jain, Sarthak Wadhera, Aditya Jandial, Charanpreet Singh, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Sreejesh Sreedharuni, Man Updesh Singh Sachdeva, Rajendra Kumar Basher, Reena Das, Pankaj Malhotra","doi":"10.31547/bct-2025-002","DOIUrl":"10.31547/bct-2025-002","url":null,"abstract":"<p><strong>Background: </strong>Bone marrow (BM) Measurable Residual Disease (MRD) assessments underestimate disease burden in multiple myeloma, as focal lesions can exist outside the marrow. Functional imaging, like positron emission tomography-computed tomography (PET-CT), offers valuable insights into residual disease beyond the marrow. Combining marrow flow cytometry (FCM) with PET-CT for a composite MRD (cMRD) assessment before and after autologous stem cell transplant (ASCT) is expected to provide prognostic information, particularly in settings where patients receive extended duration of anti-myeloma therapy prior to ASCT.</p><p><strong>Methods: </strong>In this retrospective cohort study, we evaluated the prognostic impact of cMRD in newly diagnosed multiple myeloma (NDMM) patients who underwent triplet/quadruplet-based induction followed by ASCT from January 2017 to June 2023. cMRD was assessed before ASCT and again around day 100 post-transplant. cMRD negativity was defined as undetectable residual clonal plasma cells (sensitivity 1×10^-5) on multi coloured FCM and PET-CT negativity per The International Myeloma Working Group criteria.</p><p><strong>Results: </strong>Among 106 patients undergoing ASCT, 82 had cMRD assessments before and on day 100 post-ASCT. Median pre-ASCT treatment duration was 11 months (interquartile range [IQR]: 4-18). At the pre-ASCT time point, sixty seven percent patients were bone marrow MRD negative (BM-MRD^PRE-), while 38% were PET-CT negative (PET^PRE-). Post-ASCT, these rates were 74% (BM-MRD^POST-) and 49% (PET-CT^POST-) respectively. At a median follow-up of 35 months (IQR: 23.5-58), median time to next treatment (TTNT) and overall survival (OS) were not reached. At three years, TTNT was significantly higher in patients who were cMRD-negative before ASCT compared to those who were cMRD-positive [91% (confidence interval (CI): 77-100) versus 67% (CI: 52-80); <i>p</i>=0.027]. BM-MRD^PRE- and PET^PRE- were both independently associated with improved TTNT on univariate analysis [Hazard Ratio: 0.32 (0.14-0.74) and 0.45 (0.23-0.94) respectively]. Post-ASCT cMRD status did not significantly impact TTNT [82% (CI: 68-96) versus 65% (CI: 51-69); <i>p</i>=0.116]. Three-year TTNT rates were similar among patients with and without baseline high-risk cytogenetic abnormalities (HRCA) if they maintained sequential cMRD negativity. In multivariate analysis, the absence of HRCA, complete response before ASCT, cMRD^PRE-, and sustained cMRD negativity at both time points were independent predictors of longer TTNT.</p><p><strong>Conclusions: </strong>Pre-ASCT cMRD assessment using both PET-CT and bone marrow FCM provides prognostic value in NDMM. This approach is particularly relevant in real-world settings where patients often receive prolonged induction therapy before ASCT.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"8 3","pages":"234-243"},"PeriodicalIF":0.0,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12414649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial Disparity in Myeloablative Hematopoietic Cell Transplantation Outcomes in Patients with Hematological Malignancies Older Than 45 Years.","authors":"Satarupa Mohapatra, Yasser R Abou Mourad, Hannah M Cherniawsky, Shanee S Chung, Donna L Forrest, Gagan Kaila, Florian Kuchenbauer, Katie Lacaria, Joanna MacLean, Stephen H Nantel, Sujaatha Narayanan, Thomas J Nevill, Judith A Rodrigo, Arefeh Rouhi, Claudie Roy, David Sanford, Kevin W Song, Ryan J Stubbins, Cynthia L Toze, Jennifer K White, Deepesh P Lad","doi":"10.31547/bct-2025-001","DOIUrl":"10.31547/bct-2025-001","url":null,"abstract":"<p><strong>Introduction: </strong>The impact of race on outcomes of allogeneic hematopoietic cell transplants (HCT) has long been a field of research. The Center for International Blood and Marrow Transplant Research (CIBMTR) studies have shown worse survival for Black and Hispanic patients within the first year after HCT, but rates evened out for one-year survivors. From our personal experience, we hypothesize that the outcomes of South Asians (age ≥ 45 years) receiving myeloablative conditioning (MAC) are also worse compared to other races.</p><p><strong>Methods: </strong>This is a retrospective single-centre study. All patients (age ≥ 45 years) undergoing MAC-HCT for hematological malignancies from 2011-2022 were included. The primary outcome was overall survival (OS). Secondary outcomes were non-relapse mortality (NRM), incidence of grade 2-4 acute graft versus host disease (GVHD), moderate-severe chronic GVHD and relapse incidence (RI). The survival analysis was performed using Kaplan-Meier analysis and log-rank test. The GVHD, NRM and RI rates were calculated using the cumulative incidence (CI) of competing events and the Gray test. EZR was used for statistical analysis.</p><p><strong>Results: </strong>Of the 483 patients included, there were 28 (5.8%) South Asians (SA), 73 (15.1%), other Asians (East Asians (EA)/Southeast Asians (SEA), and 382 (79.1%) Whites (W). Asians were less likely to get matched unrelated donor-HCT than Whites (SA 21%, EA/SEA 30%, W 45%, <i>p</i>=0.009). The three groups were comparable regarding the recipient and donor sex and performance status. The proportion of SA with HCT-CI ≥ 3 was significantly higher (SA 50%, EA/SEA 37%, W 31%, <i>p</i>=0.03). SA patients were more likely to be obese (body mass index ≥ 30 kg/m²) (SA 29%, EA/SEA 5%, W 19%, <i>p</i>=0.005). There were fewer cytomegalovirus (CMV) serological mismatches among the Asians (SA 25%, EA/SEA 26%, W 43%, <i>p</i>=0.009). There was no difference in the conditioning type and CD34 cell dose. However, fewer Asians received Antithymocyte globulin/post-transplant cyclophosphamide as GVHD prophylaxis (SA 39%, EA/SEA 42%, W 45%, <i>p</i>=0.0009). The median OS was significantly shorter in SA (SA 19, EA/SEA 103, W 65 months, <i>p</i>=0.04). The 2-year NRM was significantly higher in SA (SA 35.7%, EA/SEA 13.7%, W 16%, <i>p</i>=0.03). The CI of grade 2-4 acute and moderate-severe chronic GVHD was not significantly different (<i>p</i>=0.7 & 0.6). The 2-year RI was also not significantly different (SA 28.5%, EA/SEA 24.7%, W 28%, <i>p</i>=0.8).</p><p><strong>Conclusion: </strong>Our study confirms that South Asians aged ≥ 45 years have worse survival after MAC-HCT. Supportive care is unable to overcome the differences in the outcomes.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"8 3","pages":"228-233"},"PeriodicalIF":0.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12414651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late-onset immune thrombocytopenia after unrelated cord blood transplantation for chronic myelomonocytic leukemia.","authors":"Shoya Arai, Kensuke Matsumoto, Haruko Tashiro, Seiko Kato, Takaaki Konuma, Jun Ooi","doi":"10.31547/bct-2025-004","DOIUrl":"10.31547/bct-2025-004","url":null,"abstract":"<p><p>Several reports have been published on autoimmune hematologic complications, including immune thrombocytopenia (ITP), after cord blood transplantation (CBT). However, there have been no reports of late-onset ITP following CBT. A 51-year-old male with chronic myelomonocytic leukemia received unrelated CBT in 2012. During regular follow-up visits every 3-6 months, his complete blood count remained normal until March 2024. In September 2024, 12 years after the CBT, the patient suddenly developed severe thrombocytopenia. Following a diagnosis of ITP, the patient was treated with intravenous immunoglobulins and prednisone. With follow-up period of 5 months after the onset of ITP, the patient is still alive with a platelet count of 126 × 10⁹/L. This case suggests that late-onset ITP after CBT occurred suddenly and may be life-threatening. Long-term follow-ups and regular clinic visits may reduce the risk of delays in diagnosis and treatment.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"8 3","pages":"225-227"},"PeriodicalIF":0.0,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12414648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"REAL-WORLD OUTCOMES OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE TREATED WITH RUXOLITINIB.","authors":"Archita Ravindranath, Sushil Selvarajan, Sharon Lionel, Anup Joseph Devasia, Anu Korula, Fouzia N Aboobacker, Kavitha M Lakshmi, Poonkuzhali Balasubramanian, Biju George, Vikram Mathews, Aby Abraham, Uday Kulkarni","doi":"10.31547/bct-2024-033","DOIUrl":"10.31547/bct-2024-033","url":null,"abstract":"<p><p>Acute graft-versus-host disease (aGVHD) is a life-threatening complication that can develop after allogeneic hematopoietic stem cell transplantation. Patients with steroid-refractory aGVHD (SR-aGVHD) have an extremely poor prognosis. Ruxolitinib is an approved treatment for SR-aGVHD. However, there is a paucity of real-world data on the clinical outcomes of patients with SR-aGVHD treated with ruxolitinib. We conducted a retrospective analysis using hospital records of the clinical outcomes of patients who underwent stem cell transplantation at our center between January 2021 and December 2022 and developed steroid-refractory aGVHD which was treated with ruxolitinib. During the study period, 381 patients underwent allogeneic stem cell transplantation at our center. Amongst these, 160 (42.0%) developed aGVHD. Of these, 59 (36.8%) had SR-aGVHD and 40 were treated with ruxolitinib. Ruxolitinib therapy was administered after a median of 6 days (range 3-29) from onset of aGVHD. Amongst the 28 patients who survived at day 28 (12 died before the day 28 response could be assessed), a total of 16 patients (57.1%) attained a response (complete response (n=12) or partial response (n=4)). Infectious complications were the most common adverse event (n=39; 97.5%), followed by severe cytopenia (grades 3 to 4) in 25 (62.5%) patients. The median follow-up of the cohort was 5 months (range 1 to 29 months). At the last follow up, 30 (75%) patients died; 3 patients died of progression of steroid-refractory aGVHD, 14 died of progression of aGVHD with infection, 10 died of underlying infection and 3 had disease relapse. From our real-world analysis, we conclude that though the outcomes in patients with SR-aGVHD responding to ruxolitinib are encouraging, there is still a large unmet need for novel strategies for improving outcomes and reducing infection-related mortality, even while there is access to ruxolitinib.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"8 3","pages":"217-224"},"PeriodicalIF":0.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12414650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to: Impact of the COVID-19 outbreak on the field of hematopoietic cell transplantation in the Asia-Pacific region: APBMT Activity Survey 2020/2021 [Blood Cell Therapy. 2024; 7(4): 129-137. doi:10.31547/bct-2024-020].","authors":"Minako Iida, Aloysius Ho, Xiao Jun Huang, Kaiyan Liu, Meng Lv, He Huang, Yachiyo Kuwatsuka, Joon Ho Moon, Yoon Seok Choi, Jong Wook Lee, Navin Khattry, Kavitha M Lakshmi, Leonie Wilcox, Amir Ali Hamidieh, Maryam Behfar, Bor-Sheng Ko, Kim Wah Ho, Gin Gin Gan, Udomsak Bunworasate, Suradej Hongeng, Usanarat Anurathapan, Tasneem Farzana, Joycelyn Sim, Vincent Lee, Man Kit Garret Leung, Phu Chi Dung, Van Man Huynh, Wasantha Rathnayake, Prasad Abeysinghe, Marjorie Rose Bravo, Teresita Dumagay, Aye Aye Gyi, Damai Santosa, Desta Ardini, Bishesh Sharma Poudyal, Mafruha Akter, Khishigjargal Batshkh, Mikhail Drokov, Chi-Cheng Li, Shinichiro Okamoto, Alok Srivastava, Anthony Dodds, Yoshiko Atsuta","doi":"10.31547/bct-2024-020-cx","DOIUrl":"https://doi.org/10.31547/bct-2024-020-cx","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.31547/bct-2024-020.].</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"8 3","pages":"250-251"},"PeriodicalIF":0.0,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12414652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PD-1 inhibitor in patients with minimal residual disease who failed donor lymphocyte infusion or interferon after allogeneic haematopoietic stem cell transplantation.","authors":"Ling Ma, Si-Qi Li, Wei Han, Hai-Xia Fu, Yao Chen, Rui Ma, Yu-Hong Chen, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Feng-Rong Wang, Xiao-Dong Mo, Xiao-Jun Huang, Yu-Qian Sun","doi":"10.31547/bct-2024-034","DOIUrl":"10.31547/bct-2024-034","url":null,"abstract":"<p><p>This study aimed to evaluate the efficacy and safety of programmed death receptor 1 (PD-1) antibody in patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) with minimal residual disease (MRD) after allogeneic haematopoietic stem cell transplantation (allo-HSCT). Six patients were retrospectively reviewed in this study, and all had failed prior treatment (donor lymphocyte infusion or interferon) before PD-1 antibody administration. Among these 6 patients, two received PD-1 alone while four received PD-1 plus azacitidine. The median treatment with the PD-1 antibody was four doses (range, 1-7 doses). Three patients developed > grade 3 toxicity, including 2 deaths. Among the five evaluable patients, four achieved negative MRD with a median time to response of 2 months (range: 1-3 months); and the median duration of response was 105 days (range: 26-211 days). The median survival time of the five patients was 320 days (range: 107-350 days). Our data suggest that anti-PD-1 antibody in AML/MDS patients with positive MRD following allo-HSCT may be a treatment option.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"8 2","pages":"200-209"},"PeriodicalIF":0.0,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tyrosine kinase inhibitor-related factors pre-disposing to post-transplant thrombotic microangiopathy in patients with CML and Ph+ acute leukemias.","authors":"Sachin Punatar, Komal Kumbhalwar, Siddhesh A Kalantri, Anant Gokarn, Lingaraj Nayak, Akanksha Chichra, Sumeet Mirgh, Nishant Jindal, Libin Mathew, Sadhana Kannan, Navin Khattry","doi":"10.31547/bct-2024-029","DOIUrl":"10.31547/bct-2024-029","url":null,"abstract":"<p><strong>Introduction: </strong>We have previously reported that pre-transplant use of tyrosine kinase inhibitors (TKIs) is independently associated with the occurrence of transplant-associated thrombotic microangiopathy (TA-TMA). However, the precise TKI-related factors which predispose to TA-TMA are unknown. In this retrospective analysis, we identify the TKI-related factors that are associated with TA-TMA.</p><p><strong>Methods: </strong>This was a single center retrospective analysis of all patients with Philadelphia chromosome-positive (Ph+) malignancies who received BCR-ABL TKIs prior to transplant and underwent allogeneic hematopoietic stem cell transplantation (HSCT) between January 2008 and March 2019. Definite TA-TMA was defined as per Blood & Marrow Transplant Clinical Trials Network (BMT CTN) criteria and probable TMA as per Cho criteria. Details about the timing of the start and stop of TKI pre-transplant, the dose of TKIs used, and the number of TKIs exposed to pre-transplant were obtained. Imatinib > 400 mg/day, dasatinib > 100 mg/day, or nilotinib > 800 mg/day were considered as high dose TKI.</p><p><strong>Results: </strong>Seventy-two patients with chronic myeloid leukemia (CML)/Ph+ acute leukemias underwent transplant in the above period. Patient, donor, and transplant characteristics are shown in Table 1 and were well-matched between those with and without TMA. Overall, 13 (18%) had TA-TMA (median day +128), with 9 definite and 4 probable. The only TKI-related factor significantly associated with TA-TMA was the use of high-dose TKI (<i>p</i>=0.04). Among non-TKI-related factors, acute graft versus host disease (GVHD) was associated with TA-TMA (<i>p</i>=0.01). On multivariate analysis, high dose TKI did not remain statistically significant (Odds Ratio (OR) 4.6, <i>p</i>=0.16). TA-TMA was associated with significantly worse long-term survival (6-year survival was 30% with TMA versus 62% without TMA, <i>p</i>=0.026).</p><p><strong>Conclusions: </strong>Pre-transplant use of TKI was associated with risk of TMA in about one-fifth of patients. High-dose TKI and acute GVHD increased the risk of TA-TMA. Prospective studies are warranted to confirm these findings. TA-TMA was associated with significantly worse long-term survival.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"8 2","pages":"210-216"},"PeriodicalIF":0.0,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PYODERMA GANGRENOSUM WITH NON-PSEUDOMONAL ECTHYMA GANGRENOSUM IN MYELODYSPLASTIC SYNDROME TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.","authors":"Christine Faith V Tan, Lynn B Bonifacio, Minette Claire O Rosario, Adolfo C Parayno","doi":"10.31547/bct-2024-028","DOIUrl":"10.31547/bct-2024-028","url":null,"abstract":"<p><strong>Background: </strong>Co-occurrence of pyoderma gangrenosum (PG) and ecthyma gangrenosum (EG) pose diagnostic and therapeutic challenges in immunocompromised patients.</p><p><strong>Case report: </strong>A 47-year-old Filipino woman with transfusion-dependent intermediate-risk myelodysplastic syndrome (MDS) was admitted to our institution for allogeneic hematopoietic stem cell transplantation (HSCT). During the preparation for allogeneic HSCT, she developed several erythematous ulcerated lesions on the lower extremities, which were initially managed as PG. Subsequent febrile episodes and worsening lesions with isolated <i>Escherichia coli</i> in blood and tissue cultures lead to the diagnosis of EG complicating PG. She was treated through targeted antibiotics, wound debridement, and proper wound care. After the resolution of the infection and upon starting low-dose immunosuppression followed by allogeneic HSCT, her left leg lesions showed progressive improvement. Six months after HSCT, lesions were completely resolved with complete epithelialization.</p><p><strong>Conclusion: </strong>This case highlights the importance of accurate diagnosis and integrated management of complex conditions like PG and EG in immunocompromised patients. The successful resolution of lesions post-HSCT underscores the potential curative role of stem cell transplantation in managing MDS-associated PG.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"8 2","pages":"195-199"},"PeriodicalIF":0.0,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salvage UCBT with Short-Term Melphalan-based Reduced-Intensity Conditioning for Primary Graft Failure after Upfront UCBT for Fulminant Aplastic Anemia.","authors":"Mari Morita-Fujita, Tomohiro Yabushita, Satoshi Yoshioka, Nobuhiro Hiramoto, Takayuki Ishikawa","doi":"10.31547/bct-2024-023","DOIUrl":"10.31547/bct-2024-023","url":null,"abstract":"<p><p>Umbilical cord blood transplantation (UCBT) is a potential option for patients with very severe aplastic anemia (VSAA) when no suitable related or unrelated donor is available. However, the high incidence of graft failure following UCBT remains a major challenge. The optimal conditioning regimen for UCBT in aplastic anemia (AA), particularly for salvage UCBT after graft failure following an initial transplant, remains undetermined. We report the cases of two adolescent patients with fulminant aplastic anemia who successfully underwent salvage UCBT, conditioned by a short-term melphalan-based regimen for primary graft failure after initial UCBT. The regimen comprised fludarabine (30 mg/m²) on days -4 to -2, melphalan (40 mg/m²) on days -3 and -2, and total body irradiation (2 Gy) on day -1. Neutrophil engraftment occurred in both cases approximately three weeks after salvage UCBT. One patient developed grade 1 acute graft-versus-host disease (GVHD) and mild chronic GVHD, while the other experienced no GVHD. Both patients have normal complete blood counts more than two years after salvage UCBT. These cases suggest that a short-term melphalan-based regimen may be a viable conditioning option for salvage UCBT in cases of primary graft failure.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"8 2","pages":"190-194"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}